PSMD12 通过激活 Nrf2/TrxR1 通路促进非小细胞肺癌进展。

PSMD12 promotes non-small cell lung cancer progression through activating the Nrf2/TrxR1 pathway.

机构信息

Department of Thoracic Surgery, People's Hospital of Ningxia Hui Autonomous Region, No. 301, Zhengyuan North Street, Yinchuan, Ningxia, People's Republic of China.

出版信息

Genes Genomics. 2024 Mar;46(3):263-277. doi: 10.1007/s13258-023-01484-5. Epub 2024 Jan 19.

Abstract

BACKGROUND

Non-small cell lung cancer (NSCLC) contributes to the vast majority of cancer-related deaths. Proteasome 26S subunit, non-ATPase 12 (PSMD12), a subunit of 26S proteasome complex, is known to play the tumor-promoting role in several types of cancer but its function in NSCLC remains elusive.

OBJECTIVE

To explore the role and underlying mechanisms of PSMD12 in NSCLC.

METHODS

The PSMD12 expression in human normal lung epithelial cell line (BEAS-2B) and four NSCLC cell lines (A549, NCI-H1299, NCI-H1975, Calu-1) were determined by qRT-PCR and western blot. Malignant phenotypes of NSCLC cells were detected by CCK-8, EdU staining, immunofluorescence staining for E-cadherin, flow cytometry, and Transwell assays to assess cell viability, proliferation, epithelial-mesenchymal transition (EMT), apoptosis, migration and invasion. Dual luciferase assay was used to verify the regulatory role of transcription factor on the promoter.

RESULTS

We identified the upregulation of PSMD12 in NSCLC tissues based on the GEO datasets, which further verified in NSCLC and BEAS-2B cell lines. PSMD12 knockdown significantly suppressed malignant behaviors of NSCLC cells, including cell growth, invasion, and migration, while PSMD12 overexpression presented the opposite effects. Interestingly, we found that PSMD12 upregulated the tumor-promoting factor TrxR1 mRNA expression. For its potential mechanisms, we demonstrated that PSMD12 elevated transcription factor Nrf2 protein level and promoted Nrf2 nuclear translocation. And Nrf2 further increased TrxR1 promoter activity and enhanced TrxR1 transcription. Meanwhile, we proved that TrxR1 overexpression erased the inhibitory effect of PSMD12 knockdown.

CONCLUSION

PSMD12 promotes NSCLC progression by activating the Nrf2/TrxR1 pathway, providing a novel prognostic and therapeutic target for NSCLC treatment.

摘要

背景

非小细胞肺癌(NSCLC)导致了绝大多数癌症相关的死亡。蛋白酶体 26S 亚基,非-ATP 酶 12(PSMD12),是 26S 蛋白酶体复合物的一个亚基,已知在几种类型的癌症中发挥促肿瘤作用,但在 NSCLC 中的作用仍不清楚。

目的

探索 PSMD12 在 NSCLC 中的作用和潜在机制。

方法

通过 qRT-PCR 和 Western blot 检测人正常肺上皮细胞系(BEAS-2B)和四种 NSCLC 细胞系(A549、NCI-H1299、NCI-H1975、Calu-1)中 PSMD12 的表达。CCK-8、EdU 染色、E-钙黏蛋白免疫荧光染色、流式细胞术和 Transwell 测定评估细胞活力、增殖、上皮-间充质转化(EMT)、凋亡、迁移和侵袭,以检测 NSCLC 细胞的恶性表型。双荧光素酶测定用于验证转录因子对启动子的调节作用。

结果

我们根据 GEO 数据集确定了 PSMD12 在 NSCLC 组织中的上调,这在 NSCLC 和 BEAS-2B 细胞系中进一步得到了验证。PSMD12 敲低显著抑制了 NSCLC 细胞的恶性行为,包括细胞生长、侵袭和迁移,而 PSMD12 过表达则呈现相反的效果。有趣的是,我们发现 PSMD12 上调了促肿瘤因子 TrxR1 的 mRNA 表达。对于其潜在机制,我们证明 PSMD12 上调了转录因子 Nrf2 蛋白水平并促进了 Nrf2 核转位。并且 Nrf2 进一步增加了 TrxR1 启动子活性并增强了 TrxR1 转录。同时,我们证明了 TrxR1 过表达消除了 PSMD12 敲低的抑制作用。

结论

PSMD12 通过激活 Nrf2/TrxR1 通路促进 NSCLC 进展,为 NSCLC 治疗提供了一个新的预后和治疗靶点。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索